Aligos Therapeutics annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Aligos Therapeutics R&D Spending Growth & History (ALGS)
Aligos Therapeutics's r&d spending was $69.5M for fiscal 2025.
View full Aligos Therapeutics company overviewAligos Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $69.5M | −$816,000 | −1.16% |
| 2024 | 2024-12-31 | $70.3M | −$2.8M | −3.79% |
| 2023 | 2023-12-31 | $73.0M | −$12.0M | −14.15% |
| 2022 | 2022-12-31 | $85.1M | −$19.1M | −18.32% |
| 2021 | 2021-12-31 | $104.2M | $24.3M | +30.37% |
| 2020 | 2020-12-31 | $79.9M | $35.9M | +81.41% |
| 2019 | 2019-12-31 | $44.0M | — | — |
Aligos Therapeutics quarterly r&d spending
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $24.1M | $10.1M | +72.08% |
| Q1 2026 | 2026-03-31 | $23.4M | $8.8M | +61.03% |
| Q4 2025 | 2025-12-31 | $17.0M | $1.0M | +6.29% |
| Q3 2025 | 2025-09-30 | $23.9M | $7.2M | +42.70% |
| Q2 2025 | 2025-06-30 | $14.0M | −$7.1M | −33.76% |
| Q1 2025 | 2025-03-31 | $14.5M | −$1.9M | −11.39% |
| Q4 2024 | 2024-12-31 | $16.0M | −$6.2M | −27.98% |
| Q3 2024 | 2024-09-30 | $16.8M | $907,000 | +5.72% |
| Q2 2024 | 2024-06-30 | $21.1M | $4.3M | +25.73% |
| Q1 2024 | 2024-03-31 | $16.4M | −$1.8M | −9.75% |
| Q4 2023 | 2023-12-31 | $22.3M | $3.2M | +16.53% |
| Q3 2023 | 2023-09-30 | $15.9M | −$1.9M | −10.81% |
| Q2 2023 | 2023-06-30 | $16.8M | $271,000 | +1.64% |
| Q1 2023 | 2023-03-31 | $18.1M | −$13.5M | −42.75% |
| Q4 2022 | 2022-12-31 | $19.1M | −$9.5M | −33.21% |
| Q3 2022 | 2022-09-30 | $17.8M | −$10.3M | −36.76% |
| Q2 2022 | 2022-06-30 | $16.5M | −$8.0M | −32.76% |
| Q1 2022 | 2022-03-31 | $31.7M | $8.8M | +38.51% |
| Q4 2021 | 2021-12-31 | $28.6M | $518,000 | +1.84% |
| Q3 2021 | 2021-09-30 | $28.1M | $10.8M | +62.31% |
| Q2 2021 | 2021-06-30 | $24.6M | $7.4M | +42.96% |
| Q1 2021 | 2021-03-31 | $22.9M | $5.6M | +32.18% |
| Q4 2020 | 2020-12-31 | $28.1M | — | — |
| Q3 2020 | 2020-09-30 | $17.3M | $5.6M | +47.77% |
| Q2 2020 | 2020-06-30 | $17.2M | — | — |
| Q1 2020 | 2020-03-31 | $17.3M | — | — |
| Q3 2019 | 2019-09-30 | $11.7M | — | — |
Aligos Therapeutics r&d spending trends
Over the last five fiscal years, Aligos Therapeutics's r&d spending decreased from $79.9M to $69.5M, a change of −$10.4M. The latest reported quarter, Q2 2026, shows $24.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aligos Therapeutics source filings ↗